Senses Disorder TRIZ Cases

Polyamine or amine moieties act as intermediary carriers to improve active-agent transport across mucosal and epithelial barriers.

Measuring SHH, DHH, and IHH in biological samples with ELISA provides biochemical evidence for diagnosing taste and smell disorders.

Limited photoreceptor rescue is addressed with dose-dependent intravitreal rhBDNF delivery to protect retinal function in rhodopsin-mediated disease.

A telomerase-derived peptide inhibits choroidal neovascularization, offering an alternative mechanism to frequent anti-VEGF antibody injections in macular degeneration.

Partial OCT4, SOX2, and KLF4 expression reverses aging marks while preserving cell identity and limiting teratoma risk.

Genetically modified mesenchymal stem cells continuously secrete FGF21 and GLP-1 to regulate glucose and lipid metabolism in diabetes.

Carboxamide derivatives inhibit BRD proteins and acetyl-lysine binding to suppress inflammation linked to retinal degeneration and treatment resistance.

Corneal barriers and tear drainage limit lipophilic drug uptake; cationic hyaluronic acid-coated spanlastics improve permeability and ocular retention.

Polymerization cycles and chromatography isolate tubulin carboxypeptidase activity, while alpha-tubulin peptides enable mechanism-based inhibition.

An FcεRIα extracellular-domain dimer uses high sialic acid content to bind IgE strongly, persist longer, and reduce side effects.

Combining a selective S1P1 agonist with fumarate derivatives targets immune activation while simplifying autoimmune treatment schedules.

Dissociated fetal neural retinal cells are cultured and injected to support photoreceptor integration while improving visual function.

See how inducible OCT4, SOX2, and optional KLF4 expression reverses epigenetic aging marks while preserving cellular identity.

Specialized glasses and contact lenses introduce retinal blur to reduce spatial frequency and help limit excessive eye lengthening.

Selective TL1a-binding antibodies inhibit the TL1a/DR3 interaction while preserving DcR3 binding for colitis treatment.

Form II provides a thermodynamically stable crystalline form of Compound (I) for high-purity, large-scale preparation.

Small molecules and peptide intermediaries target SOX18 interaction domains to block partner recruitment and reduce angiogenesis.

Mechanical dissociation avoids protease-related cell lysis and DNA extrusion while supporting viable, higher-yield retinal progenitor cell cultures.

Large OTOF size limits standard delivery; split vectors recombine in cells to produce functional protein for hearing-loss treatment.

Anti-connexin 43 antibodies block hemichannel opening to reduce retinal ganglion cell loss, neuroinflammation, and nerve damage in eye disease.

The hyaluronic acid-dye conjugate improves corneal dye penetration while an LED contact lens activates cross-linking for shape correction.

Codon-optimized CNGA3, CNGB3, and REP-1 sequences in rAAV vectors target retinal protein defects linked to vision loss.

Excipients and processed silk create adaptable products across medicine, agriculture, and materials while balancing versatility with manufacturing complexity.

Novel 3,5-disubstituted compounds target autotaxin to address weak inhibition in cancer, fibrosis, and inflammatory disease treatment.

Segmented CDR and framework optimization targets TSLP with antibodies while addressing development complexity and allergic inflammation.

Quinazoline derivatives target potent LPA2 inhibition, helping lower dosage needs and adverse events in fibrosis treatment.

Conjugating butylphthalide with dexborneol is used to improve blood-brain barrier penetration and combine multi-target brain protection for ischemic stroke.

IGF-1R antibodies target autoimmune signaling in active thyroid eye disease to reduce proptosis and clinical activity.

A modified CDR sequence gives hAAG5D8 high-affinity PD-L1 binding, blocking PD-1 signaling to restore T cell function and inhibit tumors.

Hydrophobic, structurally sensitive Wnt proteins complicate purification; tetravalent antibodies activate FZD/LRP5/6 signaling and support barrier function.

Tocopherol helps hydrophilic thymol cross the corneal membrane, increasing ocular bioavailability and supporting posterior-eye treatment.

ASOs bind retained introns in pre-mRNA to promote constitutive splicing, raising mature mRNA and target protein levels.

Subretinal AAV delivery of human NMNAT1 targets retinal cells to stabilize nuclear NAD+ and preserve retinal structure and function.

Modifying ISL1 and BHLHE23 prevents bipolar differentiation so photoreceptors mature and contact host cells more effectively after transplantation.

Anticholinergic agents target Demodex mites in hair follicles and skin, addressing suppressive treatment limits and irritation.

CD73 and CD276 antibody selection separates rod progenitor cells to improve purity and viability while supporting extracellular vesicle production for retinal disease.

Cationic and aromatic peptide residues bind cardiolipin to stabilize mitochondrial membrane potential and reduce oxidative stress.

Formula I–IV compounds inhibit aberrant complement activity to limit healthy-tissue damage in immune, renal, cardiovascular, and neurological disorders.

Deuterated water helps ophthalmic formulations resist base-catalyzed hydrolysis, retain active agents, and improve eye tolerance.

Histatin peptides help inhibit apoptosis after eye or skin injury, reducing keratocyte and keratinocyte loss with one therapeutic composition.

This case uses ammonium lactate to protect damaged sensory hair cells without compromising gentamicin's antibacterial effectiveness.

This case uses 8 mg aflibercept with staged monthly and quarterly dosing to reduce injections while monitoring tolerability.

This case combines IL-6 CDR sequence optimization with Fc-domain mutations for sustained ocular blockade and reduced systemic effects.

This case uses ophthalmic spinosyn formulations to reduce Demodex mites while supporting ocular safety and relieving inflammation.

Engineered Cpf1 and guide RNA modules simplify multiplex genome targeting across mammalian, plant, and other eukaryotic cells.

This case uses PEG-linked iron oxide nanoparticles with tuned pMHC density to expand TR1 cells and suppress autoimmune responses.

This case examines IGF-1R antibody dosing to address relapsing glucocorticoid results and reduce clinical activity and proptosis.

A NIPAAm, acrylic acid, and hydrophobic-monomer gel improves ocular anchorage and bioavailability with sustained, degradable release.

This case uses monthly loading before 8- or 16-week aflibercept maintenance to limit diabetic retinopathy progression.

Boron-containing prodrugs improve posterior eye delivery while limiting hyperemia.